



# Cardio-Onco Biomarker Panel



Cardiovascular problems in successfully treated cancer patients is recognized as a major clinical problem. An increased number of cancer patients defeats the disease, but suffer from therapy induced cardiovascular complications later in life. Assessing the cardiovascular health of cancer patients prior, during and post treatment reduces these complications.

## Cardiotoxicity

the damaging effect of cancer therapy (chemotherapy and radiation) on the heart and blood vessels.

This can result in:

- Heart failure
- Pericarditis
- Hypertension
- Arrhythmias

## Risk Factors

- Existing cardiovascular diseases (CVD)
- Classical risk factors such as smoking, obesity, family history of CVD
- Type, duration dose of therapy

## Cardiovascular Diagnostics

- Circulating proteins such as troponins natriuretic peptides are gold standard biomarkers for the detection of direct myocardial damage and stress.
- Imaging techniques can be used to determine cardiac function, cardiac dimensions and status of the vasculature.

## Our cardio-onco biomarker panel

Our cardio-onco panel consists of the following markers

- NT-ProBNP
- hsTnT
- CKMB
- CK
- CRP
- Cystatine C

## When to assess the cardiovascular status of a cancer patient?

For optimal results, the cardiac condition of a cancer patient should be assessed, **prior to, during and post** treatment. This allows the oncologist to adapt therapeutic strategies or to refer a patient to a cardiologist in case of an aberrant biomarker profile.

## miRNAs – a new class of promising biomarkers

RNA, and especially non-coding RNAs such as miRNAs, are increasingly recognized as a new class of biomarkers for diseases such as cancer and cardiovascular disorders. ACS Biomarker developed a validated qPCR pipeline for the accurate and reproducible analysis of RNA biomarkers, including low abundant miRNAs, from a wide range of biological sources.

## miRNA Biomarkers

Next to the gold standard protein markers we also offer miRNA biomarker profiling. We selected a series of the most promising cardiovascular circulating miRNAs associated with CVD diagnostics. You can read more about this service in our RNA profiling technote

## What do we need?

For the full protein biomarker panel we need the following samples:

- Serum
- 900 µl
- -80°C frozen
- If possible submitted in FluidX tubes